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Aim Heart disease is recognized as a consequence of dysregulation of cardiac gene regulatory networks. Previously, unappre-
ciated components of such networks are the long non-coding RNAs (lncRNAs). Their roles in the heart remain to be
elucidated. Thus, this study aimed to systematically characterize the cardiac long non-coding transcriptome post-
myocardial infarction and to elucidate their potential roles in cardiac homoeostasis.
Methods
and results
We annotated the mouse transcriptome after myocardial infarction via RNA sequencing and ab initio transcript recon-
struction, and integrated genome-wide approaches to associate specific lncRNAs with developmental processes
and physiological parameters. Expression of specific lncRNAs strongly correlated with defined parameters of cardiac
dimensions and function. Using chromatin maps to infer lncRNA function, we identified many with potential roles
in cardiogenesis and pathological remodelling. The vast majority was associated with active cardiac-specific enhancers.
Importantly, oligonucleotide-mediated knockdown implicated novel lncRNAs in controlling expression of key
regulatory proteins involved in cardiogenesis. Finally, we identified hundreds of human orthologues and demonstrate
that particular candidates were differentially modulated in human heart disease.
Conclusion These findings reveal hundreds of novel heart-specific lncRNAs with unique regulatory and functional characteristics
relevant to maladaptive remodelling, cardiac function and possibly cardiac regeneration. This new class of molecules
represents potential therapeutic targets for cardiac disease. Furthermore, their exquisite correlation with cardiac
physiology renders them attractive candidate biomarkers to be used in the clinic.
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Introduction
Coronary artery disease is themost frequent cardiovascular disorder
and typically leads to acute myocardial infarction (MI) and ultimately
heart failure (HF).1,2Despite continued advances,HF is rapidly evolv-
ing into a major global epidemic requiring novel therapeutic
approaches. In the light of this, the elucidation of novel regulatory
mechanisms involved in HF pathogenesis holds the promise of iden-
tifying new avenues for this prevalent deadly disease. In the adult
heart, stress-dependant pathological haemodynamic and neurohor-
monal signals induce a maladaptive remodelling response, a process
characterized by cardiomyocyte (CM)hypertrophy, interstitial fibro-
sis, and ultimately cellular dysfunction resulting in contractile and
functional failure.2 Importantly, the hallmark of pathological remod-
elling in the adult heart is a global transcriptional reprogramming,
resulting in the reactivation of a foetal cardiac gene programme.3
At the molecular level, these signals activate a network of interacting
cardiac signal transduction cascades that converge on evolutionary
conserved cardiac transcription factors (TFs).2–4 These core TFs
(e.g. SRF, NKX2.5, MEF2c, GATA4, and Tbox factors) interact in a
combinatorial manner to elicit specific temporal and spatial gene
expression programmes that are ultimately responsible for patho-
logical remodelling.
In this context, the notion of gene regulatory networks (GRNs)
being primarily protein-based regulatory systems has been some-
what premature.5 A number of recent studies have demonstrated
that GRN activity is under the control of a myriad of interleaved
networks of non-coding RNAs (ncRNAs). Non-coding RNAs
control every aspect of GRN activity including transcriptional
control, post-transcriptional processing, and epigenetic targeting.6
The best-characterized ncRNAs in the heart are the small micro-
RNAs (miRNAs), which adjust entire functional networks of
mRNAs via post-transcriptional gene silencing, implicating miRNAs
as important stress-dependant modulators.7,8 In addition to small
ncRNAs, global transcriptomic screens have identified other func-
tional classes of transcripts, which are larger than 200 nucleotides,
collectively known as long non-coding RNAs (lncRNAs).9–11 The
functions of most lncRNAs remain unknown; however, many
have been shown to exert non-redundant roles in a diverse array
of biological processes including chromosome X inactivation,12
imprinting,13 splicing,14 and transcriptional regulation.15 In particular,
lncRNAs appear to be important for the global modulation of cell-
specific epigenomic states via directing chromatinmodification com-
plexes to their sites of action.16 Furthermore, mammalian lncRNAs
appear to be expressed in a highly cell-type and context-specific
manner.17–19 Considering the functionality of these transcripts,
lncRNAs may represent an important class of regulatory mediators
of cardiogenic lineage-specific commitment during development
andof specialized cellular functions involved inmaintaining cardiac in-
tegrity. Accordingly, themajority of cardiogenic lncRNAs functional-
ly characterized to date regulates developmental processes.20,21
However, their potential role controlling mature tissue homoeosta-
sis and adaptation to stress remains largely unexplored.
The intrinsic -cis and -trans activating and epigenomic orchestrating
properties of lncRNAs warrants the need to explore and generate
catalogues of cardiac-specific lncRNAs in diseased adult tissues.
In this study, we set out to characterize the cardiac long non-coding
transcriptome and in particular the dynamically modulated fraction
post-MI (Supplementary material online, Figure S1). We coupled
deep RNA-sequencing with ab initio transcript reconstruction, and
integratedgenome-widedata sets to systematically identify andanno-
tate novel heart-specific lncRNAs.We show that these lncRNAs are
highly cardiac and context specific, correlating with cardiac physi-
ology, suggesting a role as modulators of the pathological response.
Using functional inference based on developmental chromatin state
transitions, we functionally annotated these novel lncRNAs demon-
strating that they are predominantly implicatedwith cardiac develop-
mental, structural, and functional gene programmes. In particular,
novel lncRNAs are predominantly associated with active enhancer
states. We validated several novel lncRNAs in developmental and
pathological models in vitro and in vivo, and demonstrate that the
expression of specific novel lncRNAs is closely associated with
individual cardiac patho-physiological traits. Finally, we identified
hundreds of predicted human orthologues and validated their
expression in human samples. A number of these validated human
orthologues were differentially expressed in human heart disease,
supporting conserved roles in cardiac remodelling. Collectively,
we have described a novel class of mammalian heart-specific
lncRNAs with unique regulatory and functional characteristics,
relevant to maladaptive pathological remodelling, cardiac function,
and potentially regeneration. Further characterization of these
novel lncRNAs could provide unprecedented opportunities for diag-
nosis and therapeutic intervention.
Methods
Cardiac injury models: microsurgery
Ligation of the left anterior descending artery: MI in mice (C57/BL6;
males; 12 weeks of age) was induced, as previously described. See
Supplementary material online, extended experimental procedures.
Echocardiography
Transthoracic echocardiographies were performed using a 30-MHz
probe and the Vevo 770 Ultrasound machine (VisualSonics, Toronto,
ON, Canada).
RNA purification and selection of
representative samples for RNA sequencing
Total RNAwas isolated frommouse hearts using the RNeasy isolation kit
(Qiagen)2weeksafter infarction. Expressionof selected cardiacmarkers,
i.e.Nppa,Nppb,Myh6,Mhy7,Col1a, Postn, andTgfb1,wasdetermined in
sham-operated and infarcted heart samples. Four samples in each group
were selected for RNA-sequencing based on expected patterns of gene
expression known to be representative of normal vs. pathological hearts,
i.e. significant increased expression of Nppa, Nppb, Mhy7, Col1a, Postn,
and Tgfb1, and decreased expression of Myh6 in infarcted heart when
compared with sham-operated hearts. Samples were also selected on
echocardiographic parameters, in particular control hearts demon-
strated normal ejection fraction (EF) (.45%), whereas infarcted heart
showed decreased EF (,15%).
RNA-sequencing and analysis
Sequencing libraries were prepared according to Illumina RNA Seq
library kit instructions with Poly(A) selection. Libraries were sequenced
with the Illumina HiSeq2000 (2 × 100 bp). Paired-end RNAseq reads
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were mapped and analysed as described in Supplementary material
online, extended experimental procedures.
Primary cell cultures and transfection
Please refer to Supplementary material online, extended experimental
procedures.
Embryonic stem cell differentiation
Mouse embryonic stem (ES) cells were differentiated into CMs as
described previously.22
RNA expression
RNAwas isolated using the RNeasy Kit (Qiagen) according to manufac-
turer’s instructions, using on column DNase treatment. Complimentary
DNAwasgeneratedusing the SuperScript III kit (Invitrogen)with random
hexamer primers. Quantitative real-time PCR (qRT–PCR) was carried
out using the Applied Biosystems SYBR Green and TaqMan PCR kit
and an ABI Prism 7500 cycler and analysed using the DDCt method.
Chromatin-based integrated analysis
For details see Supplementary material online, extended experimental
procedures.
Human samples
For details see Supplementary material online, extended experimental
procedures.
Statistical analysis
Data throughout the paper are expressed as means+ SEM. One-way
ANOVA was used to test significance of data comparisons between
experimental groups, with P-values ,0.05 were considered significant
(95% confidence interval).
Accession numbers
Data sets have been deposited in the Gene Expression Omnibus
Database under accession number GSE52313.
Results
Global identification of long non-coding
RNAs expressed in the heart and regulated
during myocardial infarction
We first set out to characterize global transcriptional regulation
during myocardial adaptation to stress for both the coding and non-
coding transcriptomes. We utilized a well-characterized patho-
physiological model of cardiac stress in the mouse, namely MI
obtained by left anterior descending artery ligation. Fourteen days
post-infarction, the myocardium was characterized by intense re-
modelling, decreased cardiac function and induction of cardiac
markers of stress (Nppa, Nppb, Myh7, Col1a1, Postn, and Tgfb1)
(Supplementary material online, Table S1). We then identified
lncRNAs expressed in the infarcted adult mouse heart via RNA-
sequencing and ab initio transcriptome reconstruction of carefully
selected control (sham-operated hearts) and infarcted samples
based on those best representing the maladaptive remodelling
response of a large group (n ¼ 17, data not shown) (Supplementary
material online, Figure S2A). Massive parallel sequencing was used to
obtain paired-end reads of experimental libraries from the border
zone (BZ) of four infarcted hearts and four corresponding regions
of sham-operated non-infarcted hearts, and Cufflinks23 was utilized
to perform ab initio transcript assembly on mapped paired-end
reads. Immediately, post-MI the mammalian heart gradually evolves
into three distinct regions, the infarct, BZ, and remote zone (RZ)
(Supplementary material online, Figure S2B and C). Of these
regions the BZ, which is located between infarct and RZ, is the loca-
tion of significant biological processes including inflammation and fi-
brosis, and is thought to be of importance for the immediate adaptive
response and subsequent long-term remodelling that ultimately
leads to HF. We therefore sequenced the transcriptome of the BZ
to ensure the identification of transcripts involved in these key re-
modelling processes.
This analysis reconstructed 17 584 multi-exonic transcripts, of
which 15 075 (2204 up-regulated and 1338 down-regulated) corres-
pond to University of California Santa Cruz (UCSC)-annotated
protein-coding genes (Figure 1A–F).Our lncRNAannotationpipeline
identified 2509 multi-exonic lncRNAs (.200 bp). There were 988
(67 up-regulated and 66 down-regulated) UCSC-annotated
lncRNAs and 1521 (86 up-regulated and 225 down-regulated)
novel unannotated lncRNAs, encompassing all known lncRNA locus-
types (Figure 1E). To verify the non-coding nature of our novel
lncRNA candidates, we used the GeneID-coding potential score
and found that these novel transcripts have minimal protein-
coding potential, comparable with UCSC-annotated lncRNAs
(Figure 1D). Furthermore, novel lncRNAs and UCSC lncRNAs
were expressed at significantly lower levels than coding genes
(Figure 1C). Novel and UCSC lncRNA exons were less conserved
than coding exons although promoters were equally conserved
(Figure 1B).
We further characterized the basic features of novel lncRNAs,
comparing them with UCSC-coding genes and lncRNAs where ap-
propriate. The size of the novel lncRNA transcripts was comparable
with coding genes and slightly greater than annotated lncRNAs even
if they had fewer exons than both annotated transcript classes
(Supplementary material online, Figure S2H–J). Approximately 70%
of all novel lncRNAs have three exons or less (40% having only
two exons). To validate that the cDNA libraries of the Sham and
MI samples represent a transcriptome associated with infarction-
dependant remodelling, we first analysed well-characterized stress
marker expression in the RNA-Seq data and showed their appropri-
ate modulation (Supplementary material online, Figure S2D). In add-
ition, several novel lncRNAs demonstrated changes in expression
(Supplementary material online, Figure S2D and K). Furthermore,
globally, the cardiac transcriptome correlated well within Sham
samples, and to an independent ENCODE adult heart RNA-Seq
data set (Supplementary material online, Figure S2E and F ).24 Un-
supervised hierarchical clustering of all UCSC coding, lncRNA, and
novel lncRNA transcripts identified two distinct clusters corre-
sponding to the Sham and MI cDNA libraries demonstrating that
the transcriptome was sensitive to and representative of the pheno-
typic adaptation observed in the heart post-MI (Supplementary ma-
terial online, Figure S2G ).
Long non-coding RNAs are potent post-transcriptional modula-
tors of gene expression via their ability to act as competitive
endogenous RNAs (ceRNAs) for miRNAs.25 To investigate whether
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the cardiac lncRNA transcriptome may be involved in cardiac-
specific ceRNA networks, we selected three miRNAs known to be
modulated in the heart after infarction and determined the putative
target lncRNAs and mRNAs. We generated miRNA–lncRNA–
mRNA correlation networks with modulated miRNAs and target
transcripts visualized in Hive plots, where miRNAs, mRNAs, and
Figure1 Global identification of long non-coding RNAs expressed in the heart duringmyocardial infarction . RNA-Seq duringmyocardial infarc-
tionwas performedon border zone and shamoperated samples to characterize the infarction associated transcriptome. (A) Pie chart showing com-
position of PolyA+ transcriptome, UCSCmRNAs (blue) UCSC long non-coding RNAs (green) and novel long non-coding RNAs (red). Transcript
numbers in each group are indicated in brackets (B) Kernel density plots of phastCons score distribution of UCSCmRNA, UCSC long non-coding
RNA, novel long non-coding RNA, and random intergenic sequence for exons, introns, and promoters. (C) Kernel density plot of the transcript
abundance [fragments per kilobases per million reads (FPKM)] of UCSC mRNAs, UCSC long non-coding RNAs and novel long non-coding
RNAs. (D) Kernel density plot of coding potential (Gene ID score). (E) Number of long non-coding RNA genes in orientations relative to
nearby coding genes (F ) Heatmaps showing hierarchical clustering of differentially expressed transcripts within the three RNA classes after myo-
cardial infarction.
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lncRNAs are presented on three axes, and the arcs connecting the
axes represent positive (red) and negative (blue) correlation
between nodes (Supplementary material online, Figure S2L). It was
particularly striking that lncRNAs correlated positively with these
miRNAs, whereas mRNAs correlated negatively. Moreover, the
miRNAs appeared to target common lncRNAs andmRNAs in a syn-
ergistic manner (Supplementary material online, Figure S2M). These
findings are consistent with the implication of lncRNAs as decoys for
miRNAs.
Novel long non-coding RNAs are heart
specific and proximal to cardiac
developmental genes
The majority of lncRNAs identified in our analysis represents novel
lncRNAs that have previously escaped annotation. This could
reflect inpart thehigh levelsof cell and tissue specificity typically asso-
ciated with lncRNAs. We, therefore, computationally realigned 17
mouse non-cardiac ENCODE RNA-Seq data sets,24 and found that
16% of UCSC mRNAs and 23% of UCSC lncRNAs were classified
as heart specific (Figure 2A and B, see Supplementary material
online for a detailed definition of the heart specificity score). In con-
trast, 38% of the novel lncRNAs were heart-specific, a significant
enrichment vs. UCSC mRNAs and lncRNAs (novel lncRNA vs.
mRNA: P, 2.2 × 10216, novel lncRNA vs. UCSC lncRNA: P,
6.4 × 1029). Furthermore, differentially expressed novel lncRNAs
were significantly more heart-specific than all transcript classes,
with 60% of these novel lncRNAs being classified as heart specific
(novel lncRNA vs. mRNA: P, 2.2 × 10216, novel lncRNA vs.
UCSC lncRNA: P, 2.2 × 10216) (Figure 2A and B, Supplementary
material online, Figure S3A). Heart specificity of selected candidates
was confirmed by qRT–PCR (Supplementary material online,
Figure S3B). This increased heart specificity is likely a consequence
of the association of novel lncRNAs with enhancer sequences
active in the heart. Long non-coding RNAs have been shown to regu-
late coding gene expression both in cis and in trans. If cis-regulation
was common, one would expect proximal coding genes to also be
more heart specific. In support of this, we found that overlapping,
proximal upstream or downstream coding genes were significantly
more heart-specific than the entire coding gene collection (three cat-
egories vs. all other genes: 6.4 × 1028) (Figure 2C). Furthermore,
geneontology (GO) analysis of theseproximal coding genes revealed
significant enrichment in GO biological process categories asso-
ciated with heart development, cardiac function, and transcriptional
regulation (Figure 2D). Interestingly, differentially expressed novel
lncRNAs were more associated with transcriptional control,
suggesting that modulated novel lncRNAs may be implicated in the
transcriptional reprogramming observed in the remodelling heart.
The enrichment of specific cardiac gene functions in coding genes
adjacent to novel lncRNAs raised the possibility that novel lncRNAs
acted in cis, anddirectly affected theexpressionof their chromosomal
neighbours. To test this, we studied the expression of all transcript
classes with their neighbouring coding genes post-MI, and identified
many examples of highly correlated novel lncRNA-coding gene
pairs (Supplementary material online, Table S2 and Figure S3C ).
Novel lncRNAs and their neighbouring coding genesweremore cor-
related to each other than random gene pairs. However, coding gene
pairs andUCSC lncRNAneighbourswere alsomore correlated than
random coding gene pairs (Figure 2E). Together these data suggest
that novel lncRNAs are not more correlated to their coding gene
neighbours post-infarction than expected for any given pair of neigh-
bouring loci.
The cardiac transcriptome is highly
correlatedwith cardiac physiological traits
Quantitative expression profiling using RNA sequencing has a
number of significant advantages over hybridization-based array
methods. Arguably, the greatest advantage is the greater dynamic
range in transcript abundance determination. These unique charac-
teristics lend global transcriptome data sets amenable to direct cor-
relation profiling with continuous traits of choice. The heart itself
represents a unique organ that can be physiologically characterized
in vivo in terms of functional contractile and remodelling parameters.
We therefore correlated the cardiac transcriptome with physio-
logical traits measured by echocardiography during MI (Sham and
MI samples were used for correlation analysis). Both the coding
and non-coding transcriptome correlated well with parameters of
cardiac dimensions and function (Figure 3); however, globally novel
lncRNAs were better correlated than UCSC lncRNAs with
all physiological traits assessed (Supplementary material online,
Figure S4A). Togain a deepermolecular insight andpotentially identify
molecular pathways associatedwith physiological traits, weexecuted
unsupervised clustering and further downstream analysis of UCSC-
coding genes and novel lncRNAs. We identified four clusters for
both coding (Figure 3A) and novel lncRNA (Figure 3C) transcripts. In
each case, these consisted of one cluster that correlated positively
with cardiac function and negatively with remodelling parameters,
one cluster with the inverse of these correlations and two clusters
with non-specific intermediate correlations. Gene ontology and
heart-specificity analyses were performed on individual clusters.
With respect to novel lncRNAs, GO analysis was executed on the
most proximal coding genes. In the coding gene group, the most
heart-specific cluster was Cluster 2 (Figure 3E), which was positively
correlated with cardiac functional traits and associated with genes
involved inmitochondrial biology (Figure 3A). The least heart-specific
cluster (Cluster 4) was positively correlated with remodelling and
associated with genes involved in wound healing and extracellular
matrix (Figure 3A). Within novel lncRNAs, the most heart-specific
cluster, i.e. Cluster 4 (Figure 3F), was again positively correlated
with cardiac function associated traits. Proximal coding genes to
novel lncRNAs in Cluster 4 were enriched with heart development
associated processes (Figure 3C). Since novel lncRNAs that corre-
lated strongly with particular physiological traits were likely to be
involved in biological processes associated with those traits, these
findings indicated that novel lncRNAs within this cluster could re-
present a class of cardiac-specific regulators of developmental gene
programmes, which was reactivated in the damaged myocardium.
The least heart-specific clusters were clusters one and two, which
was positively correlated with remodelling traits.
These data demonstrated that unsupervised clustering of
transcripts was able to distinguish physiological traits. In addition,
it indicated that lncRNAs could represent specific markers of
particular physiological traits. To test this, we compared correlation
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Figure 2 Tissue specificity of novel long non-coding RNAs. Novel long non-coding RNAs aremore heart-specific and proximal to cardiac devel-
opmental genes. (A) Clustering of all and differentially expressed UCSC mRNAs, UCSC long non-coding RNAs and novel long non-coding RNAs
across Sham-operated hearts, infarcted hearts, ENCODE heart and 17 non-cardiac mouse tissues. Left-hand panels highlight cardiac-specific tran-
scripts in red. (B)Heart specificity of all and differentially expressedUCSCmRNAs,UCSC long non-coding RNAs and novel long non-coding RNAs.
(C) Heart specificity of all UCSC coding genes compared with UCSC coding genes proximal to novel overlapping downstream and upstream long
non-codingRNAs. (D) Enriched geneontology terms for genes closest to all, differentially expressed andheart-specific novel longnon-codingRNAs.
(E) Kernel density plot displaying correlation of RNA expression for random gene pairs, neighbouring coding gene pairs, UCSC long non-coding
RNA coding gene pairs and novel long non-coding RNA coding gene pairs during myocardial infarction.
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Figure3 Physiological clustering of the cardiac transcriptome. The cardiac transcriptome is highly correlatedwith cardiac physiological traits. (A)
Clustering of UCSC mRNAs based on correlation of expression with echocardiography-derived physiological traits after myocardial infarction
(Sham-operated and myocardial infarction samples were used for correlations). Clusters are illustrated right of the heatmap with top-enriched
gene ontology terms for coding genes in each cluster displayed. (B) Kernel density plots of correlation of mRNA expression with selected physio-
logical traits (ejection fraction,myocardial infarction trace, interventricular septal, and left ventricular internal diameter)withineachcluster. (C)Clus-
tering based on correlation of novel long non-coding RNA expression with echocardiography-derived physiological traits. Clusters are illustrated
right of the heatmapwith top-enriched terms for coding genes closest to novel long non-coding RNA. (D) Kernel density plots of correlation of long
non-codingRNAexpressionwith selectedphysiological traits (ejection fraction,myocardial infarction trace, interventricular septal, and left ventricu-
lar internal diameter) within each cluster. Heart specificity of UCSC mRNAs (E) and novel long non-coding RNAs (F) in clusters one to four.
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distributions for each UCSC-coding gene and novel lncRNA cluster,
with each of the following traits; EF, interventricular septal thickness
at systole (IVS), MI trace, and left ventricular internal diameter at
systole (LVID) (Figure 3B and D). UCSC-coding gene Clusters 2 and
4 strongly correlated with all these traits when compared with non-
specific clusters (Clusters 1 and 3) (Figure 3B). A similar pattern of
correlation was observed with novel lncRNA Clusters 2 and 4
(Figure3D). Interestingly, novel lncRNACluster1 exhibitedpoorcor-
relationwith LVID, EF, andMI trace but correlatedwellwith IVS, even
though this trait is typically associated with EF in our model (Supple-
mentary material online, Figure S4B). This unique characteristic is
likely a consequence of the exquisite context and cell-type specific
expression of lncRNAs, and has intriguing implications for the utiliza-
tion of novel lncRNAs as biomarkers.
Novel long non-coding RNAs are
associated with specific chromatin
states in the adult heart
Distinct chromatin states canbeused to annotate genomic sequence,
and can demarcate regulatory and transcribed genomic sequences.10
We investigated chromatin states at the novel lncRNAs and
compared with those associated with UCSC-coding genes and
lncRNAs utilizing publically available ChIP-Seq catalogues.24 We
produced frequency plots for chromatin states around the transcrip-
tional start sites (TSS) of novel lncRNAs andUCSC transcripts in five
adult mouse tissues (heart, kidney, liver, spleen, and testis). Modifica-
tions included H3K27me3 and H3K4me3 (associated with inactive
and active promoters, respectively) and H3K4me1 and H3K27Ac
(associated with poised and active promoters and enhancers). Add-
itionally, combinations of these modifications are associated with
specific functions, for example, H3K4me1 in combination with
H3K27Ac is associated with active enhancers while H3K27me3
and H3K4me3 together are associated with ‘bivalent’ domains
which are implicated in developmental processes.26–30 We calcu-
lated the frequencies of each chromatin state in promoters of all tran-
scripts specifically in the adult mouse heart. Novel lncRNAs were
more frequently associated with active enhancer states (H3K4me1
and H3K27Ac) when compared with UCSC-coding and lncRNA
genes (Figure 4). Considering the increased heart specificity of
novel lncRNAs, it is interesting to observe that they are significantly
enriched with active enhancer sequences, the most tissue-specific
functional elementswithin the genome. In agreementwith this obser-
vation, it has recently been shownthat enhancer-associated lncRNAs
are typically more cell/tissue-specific than promoter associated
lncRNAs.31 Conversely, novel lncRNAs were significantly less asso-
ciated with the polycomb repressed mark (H3K27me3) or bivalent
domain (H3K4me3 andH3K27me3). Therewere no readily discern-
ible differences in frequency of modifications associated with active
canonical promoters (H3K4me3) or poised promoters and enhan-
cers (H3K4me1). Toexplorewhether these differences in chromatin
states were tissue specific, we extended our analysis to non-cardiac
tissues. The enrichment of novel lncRNAs with active enhancer-
specificmarkswas less pronounced in non-cardiac tissues, suggesting
that a large fractionof the activeenhancer stateswerecardiac specific
(Figure 4A). Novel lncRNAs were sorted based on their chromatin
states across individual tissues (Clusters A to E) (Figure 4B).
Most novel lncRNAs were associated with a distinct chromatin
states in the heart, compared with all other tested tissues. Analysis
of novel lncRNAs with active states only in one particular tissue
demonstrated that novel lncRNAs with heart-specific chromatin
states were both more cardiac-specific in their expression (Supple-
mentary material online, Figure S5) and more likely to be associated
with proximal coding genes involved in heart developmental pro-
cesses (Figure 4C).
We further analysed chromatin state frequencies at thepromoters
of differentially expressed transcripts, either up or down-regulated
post-infarction. Coding genes and UCSC lncRNAs exhibited no
obvious enrichments in chromatin states associated with the up- or
down-regulated transcripts in the five tissues assessed (data not
shown). In contrast, novel lncRNAs exhibited a heart-specific enrich-
ment of active enhancer states associated with transcripts that were
down-regulated post infarction (Figure 4D). This is likely to be of
functional importance with respect to the global reprogramming of
gene expression observed post-infarction, much of which is under
the control of differentially activated and repressed cell and tissue
specific enhancers.
Finally, methylation and acetylation of histone lysine residues are
known to be critical determinants of transcriptional activity.10,29 For
coding genes, H3K4me3 enrichment at the TSS correlates with
active transcription while H3K27me3 is associated with a repressed
transcriptional state. To determinewhether novel lncRNAs exhibited
a similar correlation between chromatin state and transcription, we
integrated ChIP and RNA-Seq data sets from the adult heart. Novel
lncRNAs with H3K4me3 enrichment exhibited higher expression
than those marked by the polycomb repressing mark, H3K27me3
(Figure 4E). Interestingly, novel lncRNAs associatedwith an exclusively
active enhancer signaturewere less abundant than thosewith a canon-
ical activepromotermark, suggesting that novel lncRNAsderived from
active cardiac enhancers were less expressed compared with those
with a canonical promoter signature.
Inferring functions for novel long
non-coding RNAs based on developmental
chromatin state patterns
Pathological cardiac remodelling is associated with the global reacti-
vation of the foetal gene programme. We reasoned that many novel
lncRNAs likely represent ‘foetal’ genes with important roles during
cardiogenesis. To investigate this, we utilized ChIP-Seq data gener-
ated in a directed differentiation system that recapitulated the step-
wise differentiation of mouse ES cells to differentiated CMs.32 Rem-
iniscent of our findings in the adult heart vs. other tissues, novel
lncRNAs were enriched with active enhancer states in cardiac pre-
cursor cells (CPCs) and differentiated CM when compared with
UCSC-annotated transcripts (Figure 5A). Considering that novel
lncRNAs were discovered in the adult heart, it makes it more likely
for them to be associated with enhancers that are active in more
differentiated cell lineages (i.e. CPCs and CMs) during cardiogenic
differentiation of embryonic stem cells in vitro.
Clustering novel lncRNAs according to their chromatin state at
each stage of cardiac differentiation showed that novel lncRNAs
exhibited stage-specific chromatin state transitions (Figure 5B). This
suggested that lncRNAs likely had key roles in the developmental
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Figure4 Novel long non-coding RNAs are associatedwith specific chromatin states in the adult heart.Novel long non-coding RNAs are predom-
inantly associatedwith adult heart-specific activeenhancers (A) Bar charts of frequenciesofUCSCmRNAs (1),UCSC longnon-codingRNAs (2) and
novel long non-coding RNAs (3)markedbyH3K27me3,H3K4me3,H3K4me1,H3K4me3/H3K27Ac,H3K4me1/H3K27me3,H3K4me3/H3K27Ac,
orH3K4me3/H3K27me3 in adultmouse heart, kidney, liver, spleen, and testis. (B) Epigenetic statemapof all novel long non-codingRNAsmarked by
oneof the abovemarkers in at least one adult tissue including heart, kidney, liver, spleen, and testis. Rows are recursively clustered bymarks (clusters
A–E) in heart, kidney, liver, spleen, and testis. (C) Gene ontology terms significantly enriched in clusters A to E. (D) Mosaic plots showing the fre-
quencies of transcripts, by differential expression category (vertical blocks) and by chromatin states (coloured cells within vertical blocks). Area of
each coloured cell is proportional to frequency across all tissues; width of vertical bars is proportional to frequency of differential expression cat-
egory; height of cell is proportional to frequency of chromatin state within expression category. (E) Enhancer-associated novel long non-coding
RNAs (H3K4me1/H3K27Ac) tend to bemore lowly expressed when compared with novel long non-coding RNAs with canonical promoter signa-
tures (H3K4me3).
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Figure5 Inferring functions for novel long non-codingRNAsbasedondevelopmental chromatin state patterns.Novel long non-codingRNAs are
more typically associated with chromatin state patterns linked to cardiac development and function. (A) Bar charts of frequencies of UCSCmRNAs
(1), UCSC long non-coding RNAs (2) and novel long non-coding RNAs (3) marked by H3K27me3, H3K4me3, H3K4me1, H3K4me3/H3K27Ac,
H3K4me1/H3K27me3, H3K4me3/H3K27Ac, and H3K4me3/H3K27me3 in embryonic stem cells, mesodermal precursors, cardiac precursor
cells, and cardiomyocytes. (B) Epigenetic state map of all novel long non-coding RNA marked by one of the above markers in at least one
lineage. Rows are recursively clustered by marks in embryonic stem, mesodermal precursors, cardiac precursor cell and cardiomyocyte (clusters
A–D). (C) Heart specificity of chromatin-based clusters A–D. (D) Gene ontology terms significantly enriched in clusters A–D. (E) Pie charts illus-
trating associationsofUCSCmRNAs,UCSC longnon-codingRNAsandnovel longnon-codingRNAswithpre-determinedchromatin statepatterns
according toWamstad et al.32. (F ) Mosaic plot showing frequencies of transcripts by chromatin state cluster (horizontal blocks) and by differential
expression status (cellswithin horizontal blocks). Area of each coloured cell is proportional to frequency across all lineages. Height of horizontal bar
is proportional to frequency of cluster; width of cell is proportional to frequency of differential expression status within cluster. Cells are shaded
according to the Pearson residual, providing a measure of enrichment within each cluster. Red shading indicates that the observed frequency is
lower than expected while blue indicates greater than expected frequency. (G) The novlnc6 genomic locus is associated with a bonafide develop-
mental enhancer (red box). Lower panel is a Lac-Z stained embryo and isolated heart with in vivo enhancer activity at E11.5. Stained embryo images
were obtained from http://enhancer.lbl.gov/.
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transitions at which the chromatin state transitions occurred. For
example, novel lncRNAs with exclusively active enhancer states in
mesodermal precursors (MES) represent ideal candidates for mole-
cules involved in cardiac mesoderm specification, whereas novel
lncRNAs that gain active marks during the CPCs to CM transition
are likely involved in CM differentiation. Supporting this, we found
that novel lncRNAs with active chromatin states at the CP to CM
stages were more heart-specific and associated with coding genes
implicated in heart development (Figure 5C and D).
A previous study demonstrated that co-expressed genes during
cardiac differentiation could be functionally grouped based on differ-
ent chromatin state patterns.32 Each subgroup of genes appeared
to be involved in distinct biological processes, including signalling,
metabolism, and cardiac muscle contraction. We reasoned that
novel lncRNAs that shared specific chromatin patterns as those
described for coding genes were likely to be involved in comparable
biological processes, thus providing a novel powerful unbiased
chromatin-based proxy to functionally annotate novel lncRNAs.
We mapped the novel lncRNAs and UCSC annotated genes to pre-
determined cumulative patterns of chromatin transitions during ES
cell differentiation (ChIP clusters 1–34). We classified the novel
lncRNAs based on which chromatin pattern they were associated
with, and inferred a biological function based on the coding genes
and biological processes previously linked to each cluster (Supple-
mentary material online, Table S4).32 For clarity, we present 11
ChIP clusters and inferred biological processes associated with
each of our transcript classes. ChIP clusters 1–3 are associated
with ubiquitous housekeeping and non-cardiac developmental
processes. UCSC-coding genes and lncRNAs were enriched within
these clusters while novel lncRNAs were depleted (Figure 5E and
Supplementary material online, Figure S6A). On the other hand,
novel lncRNAs were enriched in ChIP-cluster 20 and clusters 23–
27, which are associated with cardiac developmental and functional
processes including muscle contraction. Furthermore, novel
lncRNAs associated with these inferred functions were significantly
more heart-specific, validating our functional inference approach
(Supplementary material online, Figure S6B).
We also identified ChIP-clusters that were enriched or depleted
in up- anddown-regulated novel lncRNAspost-MI, providing a func-
tional insight into the roles of novel lncRNAs in this response
(Figure 5F). Novel lncRNAs in ChIP-clusters 23 and 24 were
enriched in down-regulated lncRNAs post-infarction. These clus-
ters are associated with CM maturation and sarcomeric genes
(e.g. Myoz2 and Myl2). The enrichment of ChIP-cluster 23 and 24
novel lncRNAs in down-regulated lncRNAs could be indicative of
the re-activation of the foetal gene programme in the BZ post-
infarction and/or a loss of mature CMs. Furthermore, ChIP-clusters
enriched in up-regulated novel lncRNAs included cluster 18, which
is associated with immune and inflammatory responses (e.g. IL17b),
and cluster 28, which is associated with calcium homoeostasis and
G-protein-coupled receptor signalling (e.g. Gnb3), processes that
are typically activated in the BZ of the infarcted heart. Giving
further support to the notion that our novel lncRNAs may be
cardiac developmental associated transcripts, we mapped them to
a list of bonafide in vivo validated enhancers active specifically
within the E11.5 mouse heart.33 We found that seven of our
novel lncRNAsmap to validated cardiac enhancers (Supplementary
material online,Table S3) including novlnc6 (seebelow),whichmaps
tomm74, a cardiac enhancer specifically activewithin the embryon-
ic left ventricle (Figure 5G).
Validation of novel long non-coding RNAs
To gain confidence in our transcript nominations, we validated mul-
tiple unannotated novel transcripts by qRT–PCR. Seventeen high
priority novel candidates were selected based on their association
with specific parameters (Supplementary material online, Table S5),
and their expression was quantified in the BZ and RZ, 1 and 7 days
after infarction. Cardiac function andmorphology was stereotypical-
ly perturbed with markers of cardiac stress differentially expressed
as expected (Supplementary material online, Figure S7A and B).
The novel lncRNAs exhibited various kinetics of expression in both
the BZ and RZ during the acute and chronic phases (Figure 6A and
Supplementary material online, Figure S7C). Many lncRNAs were
down-regulated, e.g. Novlnc6 and 15, some were transiently
induced at Day 1 in both BZ and RZ (Novlnc35), while others
were gradually increased in BZ and RZ (Novlnc174). These distinct
kinetic and spatial patterns of expression demonstrate that novel
lncRNAs are dynamically regulated in response to MI, and suggest
that they likely play important roles in the adaptive process.
The two major cell types within the adult heart are CMs and
cardiac fibroblasts (FBs) with both being important in maladaptive
remodelling. To better characterize the novel lncRNAs, we quanti-
fied their expression in CMs and FBs isolated from the neonatal
mouse heart. The selected lncRNAs were either highly CM-specific
(Novlnc35), equally expressed in both cell types (Novlnc61) or pri-
marily expressed in FBs (Novlnc103) (Figure 6B). LncRNA function is
also dependant on subcellular localization. Enhancer-associated
lncRNAs tend to be more enriched in the nucleus, whereas
lncRNAs involved in post-transcriptional and translational processes
tend to be more cytoplasmic. Nuclear and cytoplasmic RNA
fractions were isolated from neonatal CMs and FBs (Figure 6C and
Supplementary material online, Figure S7D). Validated lncRNAs
were either enriched in nuclear (Novlnc174) or cytoplasmic
(Novlnc61) fractions, in addition to being equally present in both
(Novlnc15). Some lncRNAs interestingly displayed differential
nuclear vs. cytoplasmic enrichment in CMs and FBs (Novlnc90,
2103, 249, 211). This may be of functional relevance to roles in
these different cell types. We also correlated the expression of
these validated lncRNAs with physiological traits in Day 1 and Day
7 control andMI tissue samples (Figure 6D and Supplementarymater-
ial online, Figure S7E). The majority of the lncRNAs correlated well
with physiological traits both in the BZ and RZ. Interestingly, some
of our novel lncRNAs were better correlated than canonical stress
genes with cardiac function and remodelling (Supplementary mater-
ial online, Figure S7F ).
Many of the validated novel lncRNAs exhibited changes in
chromatin states during cardiogenesis in ES cells, suggesting that
they may have roles as ‘foetal’ developmental genes (Figure 6F). To
confirm this, mouse ES cells were differentiated through embryoid
body (EB) formation using the hanging drop model recapitulating
embryonic cardiac development in vitro. Novel lncRNAs were
modulated during cardiac differentiationwith expression correlating
with the dynamic changes in chromatin states observed at their pro-
moters (Figure 6E and F ). Some lncRNAs were induced late during
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Figure 6 Selection and validation of novel long non-coding RNAs. High priority candidates were selected based on their association with unique
and specific characteristics. See Supplementarymaterial online, Table S5 (A)Quantitative RT–PCR analysis of selected novel long non-coding RNAs
in Sham-operated (white bar) and infarcted heart (black bar), in the border and remote zones at 1 and 7 days post-infarction. (B) Heatmap represen-
tation of qRT–PCR analysis of long non-coding RNAs in cardiomyocytes and fibroblasts isolated from neonatal mouse hearts. (C) Heatmap re-
presentation of qRT–PCR analysis of long non-coding RNAs in the cytoplasmic or nuclear fractions of cardiomyocytes and fibroblasts from
neonatal mouse hearts. Blue indicates nuclear enrichment and red cytoplasmic enrichment. (D) Heatmap representation of correlation between
validated novel long non-coding RNA expression in the border zone and echocardiography-derived physiological traits after infarction. (E) Expres-
sion of selected novel long non-coding RNA in embryonic stem,mesodermal precursors, cardiac precursor cell and cardiomyocyte asmeasured by
qRT–PCR. (F) Heatmaps of ChIP enrichment values of different chromatin modification at TSS region of validated novel long non-coding RNA in
embryonic stem, mesodermal precursors, cardiac precursor cell, and cardiomyocyte. Colour scale is based on log10 of the ChIP signal. (G) Mouse
neonatal cardiomyocytes were transfected with GapmeRs targeting a novlnc6 or random scrambled sequence. Cells were harvested 48 h post-
transfection and assayed for Novlnc6, Bmp10, Nkx2–5, GATA4, Tbx20, Myh6, and Myh7 expression by qRT–PCR. Bars represent means+ SEM
(n ¼ 6 independent experiments). **P, 0.001; *P, 0.05.
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differentiation at theCMstage (Novlnc44,241,211,232, Figure 6E
and F; Supplementary material online, Figure S7G), and are likely
involved in terminal CM differentiation and maturation. Novel
lncRNAs exhibiting this profile were mapped to ChIP-clusters 24
and25,which arepredicted tobeassociatedwithheart development,
andparticularly z-disk and sarcomere function,whichcorresponds to
terminal cardiac maturation. Other lncRNAs were maximally
expressed at MES and CPC stages (Novlnc49, 2333) and are likely
to be involved in more transient developmental processes.
To evaluate whether novel lncRNAs could be associated with
specific functions involving regulation of cardiac protein coding
genes, we focused on Novlnc6, which fulfils several criteria and
unique features prototypical of lncRNAs including low-coding
potential (Gene ID score: 20.42; median for UCSC mRNA, UCSC
lncRNAs, andNovel lncRNAs is22.64,21.01and20.76, respective-
ly). Furthermore Novlnc6 shares a chromatin pattern in differentiat-
ing ES cells with the key cardiac signalling ligand BMP10 (ChIP-cluster
25) (Supplementary material online, Table S5, suggesting that
Novlnc6 could be involved in similar regulatory pathways. As an ex-
perimental model, we used primary isolated neonatal mouse CMs
expressing high levels of Novlnc6. Cells were transfected withmodi-
fied anti-sense oligonucleotides (GapmeRs) targeting Novlnc6
(Figure 6G). Key cardiac TFs and downstream cardiac target genes
involved in stress signalling, contractile apparatus and BMP10 signal-
ling were examined. This screen identifiedNkx2.5 and BMP10 as po-
tential targets of Novlnc6-mediated regulation. Nkx2.5 encodes a
core cardiac TF, high in the regulatory hierarchy of the cardiac
GRN and critical for the regulation of other cardiac TFs and down-
stream cardiac differentiation, structural, and maturation genes.34
Furthermore Nkx2–5 has been shown to be downstream of
BMP10 signalling during cardiac development.35 Our data support
therefore the notion that novel lncRNAs includes functionally im-
portant regulatory transcripts.
Dysregulation of human orthologues
in cardiac pathology
Considering the unique characteristics associated with the novel
lncRNAs, we searched for human orthologues. We mapped our
novel lncRNA catalogue to the human genome using TransMap,
a cross species mRNA alignment tool. TransMap maps our novel
mouse lncRNAs sequences across the human genome using syntenic
BLASTZalignments that considerconserved geneorderand synteny.
Of the 1521 novel lncRNAs, 73% were mapped to the human
genome (Supplementary material online, Table S6). To validate and
characterize predicted orthologues, we designed primers encom-
passedwithin the putative exons of three humanorthologues, corre-
sponding tomouseNovlnc6,223and244 (Supplementarymaterial
online, Figure S8B–D). Quantitative RT–PCRwas executed on RNA
isolated from the left ventricle of a healthy male. All three putative
human orthologueswere readily amplified and expressed at relative-
ly high levels (Supplementary material online, Figure S8A). To deter-
mine the potential roles of these orthologues in cardiac pathology,
we examined their cardiac expression in two independent human
heart pathologies. Patients with idiopathic dilated cardiomyopathy
(DCM) and with aortic stenosis (AOS) were assessed. These two
patient groups presented with perturbed cardiac functions and
associatedmaladaptive remodelling as expected for such pathologies
(Figure 7A and C and Supplementary material online, Table S7).
Furthermore, cardiac stress marker genes were also differentially
expressed (Figure 7B and D). In patients with DCM, novlnc6 was
significantly modulated (Figure 7B). Interestingly, the predicted
target gene of Novlnc6, i.e. the key cardiac TF Nkx2-5, was also sig-
nificantly down-regulated in patients with DCM. In contrast toDCM,
patients with AOSwere not associated with differential expression of
Novlnc6, or the predicted target geneofNovlnc6,Nkx2-5. Novlnc44,
however,was significantly down-regulated (Figure 7D). Thesedata sug-
gested that some candidate novel lncRNA human orthologues were
expressed at significant levels in the human heart, and furthermore,
are differentially modulated in human cardiac pathologies.
Discussion
Long non-coding RNAs are emerging as key regulatory components
ofGRNs.However, little is knownabout the rolesof thesemolecules
in disease-relevant organs such as the heart especially during the
adaptive response to stress. To address this we have systematically
identified and characterized the mouse long non-coding transcrip-
tome after MI. Hundreds of novel heart-specific lncRNAs with
unique functional and regulatory characteristics have been identified
for the first time.We integrated genome-wide approaches to associ-
ate novel lncRNAswith cardiac cell types, developmental processes,
physiological traits, and human disease states. By integrating global
chromatin state maps, we identified novel lncRNAs with potential
roles in both cardiac development and pathological cardiac remodel-
ling. Using chromatin-based inference, we generated biologically
meaningful functional annotations for the novel lncRNAs. We also
identified human orthologues and demonstrated that they are dysre-
gulated in human pathological states. These studies open up new
avenues to study and functionally characterize the roles of novel
heart-specific lncRNAs in pathological cardiac remodelling, physio-
logical function, and ultimately therapeutic reprogramming in the
context of regenerative therapies.
Novel long non-coding RNAs as potential
heart specific modulators of cardiac gene
programmes
The newly identified lncRNAs exhibit a striking tissue-specific
pattern of expression. This is in agreement with recent analysis of
lncRNAs in other tissues such as pancreatic beta cells and neuronal
cells.17–19 We, therefore, propose that novel lncRNAs described
here are major heart-specific sensors and/or effectors of the
cardiac stress response post-MI. We present a number of pieces of
evidence to support this conclusion. First, coding genes that are
proximal to novel lncRNAs are associatedwith heart developmental
processes and global transcriptional control. This directly implicates
novel lncRNAs in the transcriptional reprogramming that underlies
the reactivation of the foetal gene programme in the damaged
heart. In agreement with this, novel lncRNAs correlate positively in
expression with physiological traits associated with cardiac function
and negatively with traits associated with remodelling. At the chro-
matin level, novel lncRNAs that are down-regulated post-infarction
are highly associated with active heart-specific enhancer states.
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Considering that lncRNAs have emerged as key functional compo-
nents required for enhancer activity, it suggests that novel lncRNAs
underpin the global heart-specific transcriptional reprogramming
post-MI. Furthermore, chromatin state transition-derived functional
inferences demonstrate that large fractions of the novel lncRNAs are
associated with ChIP-clusters linked to very specific cardiac
structural and functional processes. Additionally, modulated
lncRNAs are overrepresented in ChIP clusters associated with bio-
logical processes implicated in the pathological stress response. For
example, up-regulated lncRNAs are enriched in inflammatory and
calcium signalling-associated ChIP clusters while down-regulated
lncRNAs are enriched in ChIP clusters linked to negative regulation
Figure7 Dysregulation of human long non-coding RNAorthologues in cardiac pathology.Human novel long non-coding RNAorthologueswere
detected and differentially modulated in pathological cardiac states. (A) Physiological parameters of the dilated cardiomyopathy patient cohorts.
(B) ExpressionofNovlnc6,Novlnc23,Novlnc44,Nkx2.5,Nppa, andCol1a2 inheart samples fromdilatedcardiomyopathypatients. (C) Physiological
parametersof the aortic stenosis patient cohorts. (D) ExpressionofNovlnc6,Novlnc23,Novlnc44,Nkx2.5,Nppa, andCol1a2 in heart samples from
aortic stenosis patients.
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of growth and to force generating contractile proteins. One such
prototypical novel lncRNA, novlnc6, is associated with a bonafide
cardiac developmental enhancer and appears to modulate the
expressionofNkx2.5 , amaster cardiacTF, critical for themodulation
of gene programmes involved in cardiogenic differentiation, matur-
ation, homoeostasis.34 Interestingly, BMP10, a key signalling ligand
for cardiogenesis, which maintains Nkx2.5 expression during devel-
opment,35 shares chromatin transition patterns with Novlnc6
during ES cell cardiac differentiation. BMP10 is significantly down-
regulated upon Novlnc6 knockdown, suggesting that Nxk2.5
modulation occurs secondary to BMP10 change in expression or
can be regulated independently by novlnc6. Finally, novel lncRNAs
were also significantly associated with cardiac miRNA networks
that have previously been shown to be post-transcriptional modula-
tors of the cardiac stress response, namelymiR-133a,2499, and 30c.
This suggests that cardiac lncRNAs could modulate gene pro-
grammes atmultiple regulatory levels, includingpost transcriptionally
via interaction with miRNAs.
Novel long non-coding RNAs as potential
biomarkers of cardiac form and function
RNA-seq-based expression profiling allowed us to correlate the
cardiac transcriptome with continuous numerical traits of cardiac
dimensions and function. Analysis of clustered coding genes revealed
that genes associated with mitochondrial biology positively corre-
lated with cardiac function and negatively with remodelling.
Free fatty acid oxidation is decreased during the transition to HF
due to repressed activity of mitochondrial fatty acid oxidation
enzymes.36,37 Our data support this metabolic shift in the mitochon-
dria.Conversely, coding genes that correlated positivelywith remod-
elling were associated with wound healing, extracellular matrix
production, and fibrosis, processes that are activated during the
physio-pathological response to stress.2 More importantly, Novel
lncRNAs correlated significantly better than annotated lncRNAs
with all physiological traits. This superior correlation with physio-
logical traits exhibited by novel lncRNAs is likely as a consequence
of their unique functional and regulatory characteristics, including
increased heart specificity, increased association with cardiac-
specific enhancer states and enrichment within functional clusters
linked to cardiac function. Clustering of novel lncRNAs identified
specific clusters that, like coding genes, correlated either positively,
or negatively with functional and remodelling-associated traits. This
allows us to functionally annotate our novel lncRNAs based on
their correlations with physiological traits in the heart post-injury.
Novel lncRNAs that correlate positively with remodelling traits are
likely, akin to coding genes, to be involved in fibrotic, remodelling,
and hypertrophic associated processes. Supporting this, we show
that novel lncRNAs that correlate best with cardiac function are in
fact the most heart-specific cluster and associated with proximal
coding genes implicated in heart development.
Although novel lncRNAs and coding genes are generally compar-
able in their correlations with physiological traits, we identified one
major distinguishing feature that dissociated their clustering with
individual traits. Novel lncRNAs contain a single cluster that corre-
lated specifically with IVS and not the linked EF. This specificity sug-
gests the existence of unique functional and regulatory attributes
associated with novel lncRNAs and therefore they could represent
powerful biomarkers of such traits. This would be especially relevant
in the context of cardiac pathologies where cardiac morphology is
affected independently of cardiac function, such as heart failure
with preserved ejection fraction (HFpEF).38 Patients with HFpEF
are difficult to diagnose; however, this pathology is characterized
with remodelling of the IVS.Novel lncRNAs inCluster 1 could there-
fore be ideal biomarkers for this pathology as they are specifically
associated with IVS independently of the linked functional trait,
EF. Further emphasizing the sensitivity of novel lncRNAs, we
demonstrate that individual novel lncRNAs correlated better with
physiological traits than genes encoding prototypical cardiac stress
markers. Furthermore, a recent study has demonstrated that human
cardiac lncRNA expression signatures, and not mRNA or miRNAs,
were able to distinguish left ventricular tissue samples from patients
suffering with ischaemic and non-ischaemic cardiomyopathies—
pre- and—post-left ventricular assist device (LVAD) unloading.39
These data complement our data demonstrating that cardiac
lncRNAs represent exquisite sensors of cardiac form, function, and
ultimately pathology. Recently, specific lncRNAs in the blood have
been demonstrated to be predictive of various cancer states.40 It
will be important to determine whether the novel lncRNAs identified
here can also be detectable in the plasma, and whether their
expression correlates with cardiac pathological states.
Cardiac novel long non-coding RNAs are
associated with specific chromatin state
transitions
Apowerful approach for the functional annotation of novel lncRNAs
is to characterize their underlying chromatin states in relevant
biological situations. Chromatin state maps were previously used
for the identification of the intergenic class of long non-coding
transcripts (lincRNAs),11 which were characterized based on the
presence of an active canonical promoter signature at their TSS
(H3K4me3) and which regulate genes primarily in -trans. Other
classes of lncRNAs are derived from active enhancers, as recognized
by thepresenceofH3K4me1andH3K27acmarks andprimarily regu-
late genes in -cis.41–43 Globally, novel lncRNAs identified here are
enriched with chromatin states marking active enhancers while rela-
tively few are associated with canonical promoter states typically
found at intergenic lincRNAs.11 A number of recent studies have
implicated ncRNAs as key functional components required for
enhancer activity and chromatin looping.41 We suspect that our
novel lncRNAs are likely involved in global heart-specific enhancer
dependant cis-regulation and thus modulators of the transcriptional
reprogramming required for the reactivation of the foetal gene
programme. This is supported by the observation that proximal
coding genes to novel lncRNAs with active states exclusive to the
adult heart are associated with heart development (foetal gene
programme) and transcriptional control (global transcriptional
programming). Moreover, enhancer-associated novel lncRNA
expression correlates with proximal coding gene expression
post-MI. Interestingly, novel lncRNAs associated with active enhan-
cer states are significantly less expressed vs. novel lncRNAs asso-
ciated with canonical active promoters. It has previously been
shown that enhancer derived transcripts are typically less stable
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than other lncRNAs, which may contribute to this difference in ex-
pression.44 Additionally, this may also reflect cis-regulatory action
of enhancer-associated lncRNAs at their genomic site of transcrip-
tion, which potentially requires lower copy number to elicit their
regulatory effects31 Furthermore, the higher association with active
enhancer states likely explains the increased heart specificity of
novel lncRNAs when compared with UCSC lncRNAs. Indeed,
Novel lncRNAs derived from tissue-specific enhancers are typically
more tissue-specific in their expression, correlating with the
unique tissue specificity of the enhancers that generate them.31
We established a novel approach for lncRNA functional annota-
tion thatutilizedpatternsof chromatin state transitionsduring thedif-
ferentiation of ES to CMs allowing us to assign novel lncRNAs to a
series of pre-determined chromatin pattern clusters corresponding
to distinct sets of functionally related genes32. We found that novel
lncRNAswere associatedwith chromatin clusters linked to very spe-
cific cardiacprocesses, includingheart developmental andcontractile
genes,whilemRNAsandUCSC lncRNAsweremoreassociatedwith
non-cardiac specific housekeeping processes. This demonstrates
that novel lncRNAs are enriched in clusters with inferred cardiac
functions during cardiac differentiation. This also provides a novel
powerful paradigm for the functional annotation of distinct classes
of lncRNAs that can be adopted in other appropriate contexts. In
addition, lncRNAs with unique specific chromatin states involved in
developmental specification and differentiation represent interesting
regulatory molecules as potential inductive and/or reprogramming
factors. For instance, a role in reprogramming has been reported in
recent work showing that a single lncRNA can promote induction
of pluripotent cells from somatic cells.45 Long non-coding RNAs
are emerging as global modulators of the epigenome via their
ability to interact with and genomically target ubiquitously expressed
chromatin readers, writers, and erasers.16 The stress pathways acti-
vated post-MI are associatedwith dynamic remodelling of chromatin
states,46 leading to net regulatory output control of multiple, simul-
taneously activated pathological networks. Novel lncRNAs
described here are likely integral to context and cardiac-specific
global modulation of these states and targeting them could provide
a powerful therapeutic approach to abrogate pathological gene ex-
pression and HF progression.
Novel long non-coding RNAs and human
cardiac pathology
The identification of novel human lncRNAs will provide a new
framework to study human cardiac patho-physiology. Our study
has revealed hundreds of human orthologues of novel lncRNAs, of
which a few candidates were shown to be modulated in two human
cardiac disease states, namely dilated cardiomyopathy and aortic
stenosis. One particular novel lncRNA, novlnc6, was significantly
down-regulated in dilated cardiomyopathy. Importantly, Novlnc6
knockdown in CMs results in a concomitant down-regulation of
BMP10 and Nkx2.5, two important regulators of CM identity. Novel
human lncRNAs identified thus represent candidate regulators of
protein coding genes implicated in human cardiac pathology. More,
generally, these results set the stage for more focused studies to
dissect the potential roles of inherited and acquired defects in novel
lncRNA genes in human cardiac disease. Furthermore, considering
that novel lncRNAswere identified in aMImodel, it would be of inter-
est to characterize the expression of human orthologues in patients
following infarction. Moreover, it is likely that novel lncRNAs might
be useful at identifying subgroups within affected individuals. In this
context, future studies should investigate the value of novel lncRNAs
as phenotypic biomarkers. Characterization of these novel lncRNAs
could therefore provide unprecedented opportunities for under-
standing disease progression, and for diagnosis and intervention.
Supplementary material
Supplementary material is available at European Heart Journal online.
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